India Regulators Probe Abbott Healthcare Over $55M Phensedyl Syrup Diversion
ABT•On January 14, Uttar Pradesh regulators inspected Abbott Healthcare’s Himachal Pradesh facility, seizing manufacturing and distribution records in a probe of codeine-based Phensedyl syrup. The inquiry follows a December 2024 production halt despite evidence of 22 million bottles (valued at $55 million) distributed and 30,000 seized in illicit channels.
1. January Pullback Presents Attractive Entry Point
Abbott Laboratories experienced a price decline of approximately 22% from its 52-week high of $141.23 to a recent trough near $110 in January 2026. This pullback followed a mixed Q4 report but reflects broader market volatility rather than fundamental deterioration. With the stock trading near its 52-week low of $105.78, valuation metrics have improved: the forward P/E is now below 24x, compared with a five-year average closer to 26x, while free cash flow yield stands near 4.5%. Long-term investors can view this retracement as an opportunity to accumulate shares at a discount to historical norms.
